The growing fentanyl crowd

Cephalon Corp. has done a nice job of turning Actiq oral transmucosal fentanyl for breakthrough cancer pain into a moneymaker. When CEPH acquired Anesta Corp. in 2000, Actiq sales were $15 million a year. This year, CEPH expects to post Actiq sales of $325-$375 million. And late last year, CEPH

Read the full 502 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers